FRANKLIN, Tenn. / Feb 21, 2025 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in three investor conferences in March.
On Tuesday, March 4, 2025, the Company will participate in the Raymond James 46th Annual Institutional Investors Conference, being held March 2-5, 2025, in Orlando, Florida. The Company’s presentation will begin at 8:05 a.m. Eastern Time/7:05 a.m. Central Time.
On Tuesday, March 11, 2025, the Company will participate in the Leerink Partners 2025 Global Healthcare Conference, being held March 10-12, 2025, in Miami, Florida. The Company’s presentation will begin at 2:20 p.m. Eastern Time/1:20 p.m. Central Time.
On Wednesday, March 12, 2025, the Company will participate in the Barclays 27th Annual Global Healthcare Conference, being held March 11-13, 2025, in Miami, Florida. The Company’s presentation will begin at 9:30 a.m. Eastern Time/8:30 a.m. Central Time.
The live webcast of all the presentations will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentations will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2024, Acadia operated a network of 260 behavioral healthcare facilities with approximately 11,300 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
| Last Trade: | US$24.53 |
| Daily Change: | 0.76 3.20 |
| Daily Volume: | 2,714,959 |
| Market Cap: | US$2.270B |
August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
